The US FDA and FTC Sign Agreement to Support the Development of Biosimilars

8. The US FDA and FTC Sign Agreement to Support the Development of Biosimilars
  • The partnership will address the false and misleading promotion about biosimilars within their respective authorities and prevent anti-competitive behavior. Additionally, the agencies will collaborate with participants from industry, academia and government agencies for discussing issues related to competition in the biologics market
  • The agencies will collaboratively exchange the information for suitable practices in preventing the activities that the biosimilar is needed for testing. Also, the FTC will review the patent settlements for preventing antitrust violations
  •  The FDA’s BAP outlines four strategies for accelerating the biosimilar competition, including supporting market competition and providing direction to industry for the development of promotional materials for medical products. The FDA and FTC will uphold a public workshop FDA/FTC Workshop on a Competitive Marketplace for Biosimilars on Mar 9, 2020 at FDA’s White Oak Campus in Silver Spring, Maryland

Click here to read full press release/ article | Ref: The US FDA | Image: Twitter